Phibro Animal Health Corporation

NASDAQ:PAHC

Drug Manufacturers - Specialty & Generic

Healthcare
$35.57 +1.23%

+$0.38 today

Market cap
$1.44B
Beta
0.46
P/E (TTM)
13.3
EPS (TTM)
$2.35
Dividend yield
1.54%
52W Low $23.57High $60.08

Volume 0.11M

Average 0.37M

PAHC EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Phibro Animal Health CorporationNASDAQ: PAHC

EBITDA · Q3 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q3 FY2026 EBITDA of $55.64M rose 8.3% year over year, behind the +80.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 10.8% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.

Context

  • EBITDA amounted to 11.3% of revenue in FY2025, up 4.5 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $258.4M (+76.0%) for the fiscal year ending Jun 2026, a slowdown from the +112.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$55.64M-10.8% QoQ
Last fiscal yearJun 2025
$146.85M+112.6% YoY
LTMMar 2026
$225.31M+80.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.3%+35.3%+27.0 pp
1 year+112.6%+76.0%-36.7 pp
3-year CAGR+7.8%+25.8%+18.0 pp
5-year CAGR+18.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
146.85M USD
Year-over-year change
+112.6%
4-year CAGR
+7.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PAHC compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +80.1% is the 2nd highest of 6, against a peer median of -23.8%.
  • EBITDA amounts to 15.0% of revenue for PAHC, versus a peer median of 21.0%.
PAHC Competitors
EBITDA for PAHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
ZTSZoetis Inc.LTM Jun 2026$3.99B USD-1.1%+6.6%42.0%
ELANElanco Animal Health IncorporatedLTM Sep 2026$679M USD-23.8%-7.9%13.2%
PAHCPhibro Animal Health CorporationLTM Mar 2026$225.31M USD+80.1%+7.8%15.0%
NEOGNeogen CorporationLTM Aug 2026$105.13M USD+112.0%+9.9%11.9%
ZYBTZhengye Biotechnology Holding LimitedFY2025-CN¥42.52M CNY-199.8%—36.5%
Peer median (excluding PAHC) —-23.8%+8.2%21.0%

Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue833.35M942.26M977.89M1.02B1.3B
Cost of Revenue561.97M656.86M679.65M704.59M896.27M
Gross Profit271.38M285.4M298.24M313.09M399.94M
Gross Margin32.6%30.3%30.5%30.8%30.9%
Research & Development00000
Selling, General & Admin196.51M206.41M226.39M259.78M289.48M
Operating Expenses196.51M206.41M226.39M259.78M289.48M
Depreciation & Amortization31.88M32.71M34.01M36.18M45.61M
EBITDA110.21M117.13M106.03M69.06M146.85M
EBITDA Margin13.2%12.4%10.8%6.8%11.3%
Operating Income74.87M78.99M71.85M53.32M110.47M
Operating Margin9.0%8.4%7.3%5.2%8.5%
Interest Income838K816K3.36M4.47M2.62M
Interest Expense10.4M12.1M17.95M21.97M33.25M
Other Income / Expenses(8.4M)(6.66M)(17.78M)(42.4M)(42.47M)
Income Before Tax66.47M72.33M54.07M10.92M67.99M
Pre-Tax Margin8.0%7.7%5.5%1.1%5.2%
Income Tax Expense12.08M23.15M21.47M8.5M19.73M
Net Income54.39M49.18M32.61M2.42M48.26M
Net Margin6.5%5.2%3.3%0.2%3.7%
EPS (Basic)1.341.210.810.061.19
EPS (Diluted)1.341.210.810.061.19
Weighted Avg Shares40.5M40.5M40.5M40.5M40.5M
Weighted Avg Shares (Diluted)40.5M40.5M40.5M40.52M40.7M

Phibro Animal Health Corporation

NASDAQ:PAHC

Intrinsic Alpha fair value

Locked

Current Price

$35.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.